[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
February 25, 2008

Concerns About Bone Safety of Tricyclic Antidepressant Therapy—Reply

Arch Intern Med. 2008;168(4):436. doi:10.1001/archinternmed.2007.115

In reply

We agree that a definitive conclusion about TCAs and their possible effects on change in bone mineral density cannot be made based on our analysis. As we discussed in our article,1 TCAs are often prescribed for indications other than depression and, when prescribed for conditions such as insomnia or chronic pain, are often prescribed at low doses. Type II error is certainly possible, given our smaller number of TCA users. Based on our number of TCA users and nonusers and the standard deviation for their rates of bone loss, we had 80% power to detect a difference of 0.35 in the means of the annualized percentage change in total hip bone mineral density.

First Page Preview View Large
First page PDF preview
First page PDF preview
×